ELITZUR, Sarah, Ajay VORA, Birgit BURKHARDT, Hiroto INABA, Andishe ATTARBASCHI, Andre BARUCHEL, Gabriele ESCHERICH, Brenda GIBSON, Hsi-Che LIU, Mignon LOH, V Moorman ANTHONY, Anja MOERICKE, Rob PIETERS, Anne UYTTEBROECK, Susan BAIRD, Jack BARTRAM, Shlomit BARZILAI-BIRENBOIM, Sandeep BATRA, Miriam BEN-HAROSH, Yves BERTRAND, Trudy BUITENKAMP, Kenneth CALDWELL, Ricardo DRUT, Ashley V GEERLINKS, Gil GILAD, John GRAINGER, Stephanie HAOUY, Nicholas HEANEY, Mary HUANG, Danielle INGHAM, Zdenka KŘENOVÁ, Michaela KUHLEN, Thomas LEHRNBECHER, Atsushi MANABE, Felix NIGGLI, Claudia PARIS, Shoshana REVEL-VILK, Pierre ROHRLICH, Mohamad G SINNO, Tomasz SZCZEPANSKI, Melanie TAMESBERGER, Rajasekharan WARRIER, Matthias WOLFL, Ronit NIREL, Shai IZRAELI, Arndt BORKHARDT a Kjeld SCHMIEGELOW. EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy. Blood. Washington DC, USA: American Society of Hematology, 2023, roč. 141, č. 7, s. 743-755. ISSN 0006-4971. Dostupné z: https://dx.doi.org/10.1182/blood.2022016975.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy
Autoři ELITZUR, Sarah (garant), Ajay VORA, Birgit BURKHARDT, Hiroto INABA, Andishe ATTARBASCHI, Andre BARUCHEL, Gabriele ESCHERICH, Brenda GIBSON, Hsi-Che LIU, Mignon LOH, V Moorman ANTHONY, Anja MOERICKE, Rob PIETERS, Anne UYTTEBROECK, Susan BAIRD, Jack BARTRAM, Shlomit BARZILAI-BIRENBOIM, Sandeep BATRA, Miriam BEN-HAROSH, Yves BERTRAND, Trudy BUITENKAMP, Kenneth CALDWELL, Ricardo DRUT, Ashley V GEERLINKS, Gil GILAD, John GRAINGER, Stephanie HAOUY, Nicholas HEANEY, Mary HUANG, Danielle INGHAM, Zdenka KŘENOVÁ (203 Česká republika, domácí), Michaela KUHLEN, Thomas LEHRNBECHER, Atsushi MANABE, Felix NIGGLI, Claudia PARIS, Shoshana REVEL-VILK, Pierre ROHRLICH, Mohamad G SINNO, Tomasz SZCZEPANSKI, Melanie TAMESBERGER, Rajasekharan WARRIER, Matthias WOLFL, Ronit NIREL, Shai IZRAELI, Arndt BORKHARDT a Kjeld SCHMIEGELOW.
Vydání Blood, Washington DC, USA, American Society of Hematology, 2023, 0006-4971.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30204 Oncology
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 20.300 v roce 2022
Kód RIV RIV/00216224:14110/23:00131032
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1182/blood.2022016975
UT WoS 000968991200001
Klíčová slova anglicky EBV-driven lymphoid neoplasms; pediatric ALL; maintenance therapy
Štítky 14110317, 14110321, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 14. 2. 2024 09:44.
Anotace
The development of a second malignancy after the diagnosis of childhood acute lymphoblastic leukemia (ALL) is a rare event. Certain second malignancies have been linked with specific elements of leukemia therapy, yet the etiology of most second neoplasms remains obscure and their optimal management strategies are unclear. This is a first comprehensive report of non-Hodgkin lymphomas (NHLs) following pediatric ALL therapy, excluding stem-cell transplantation. We analyzed data of patients who developed NHL following ALL diagnosis and were enrolled in 12 collaborative pediatric ALL trials between 1980-2018. Eighty-five patients developed NHL, with mature B-cell lymphoproliferations as the dominant subtype (56 of 85 cases). Forty-six of these 56 cases (82%) occurred during or within 6 months of maintenance therapy. The majority exhibited histopathological characteristics associated with immunodeficiency (65%), predominantly evidence of Epstein-Barr virus-driven lymphoproliferation. We investigated 66 cases of post-ALL immunodeficiency-associated lymphoid neoplasms, 52 from our study and 14 additional cases from a literature search. With a median follow-up of 4.9 years, the 5-year overall survival for the 66 patients with immunodeficiency-associated lymphoid neoplasms was 67.4% (95% confidence interval [CI], 56-81). Five-year cumulative risks of lymphoid neoplasm- and leukemia-related mortality were 20% (95% CI, 10.2-30) and 12.4% (95% CI, 2.7-22), respectively. Concurrent hemophagocytic lymphohistiocytosis was associated with increased mortality (hazard ratio, 7.32; 95% CI, 1.62-32.98; P =.01). A large proportion of post-ALL lymphoid neoplasms are associated with an immunodeficient state, likely precipitated by ALL maintenance therapy. Awareness of this underrecognized entity and pertinent diagnostic tests are crucial for early diagnosis and optimal therapy.
Návaznosti
MUNI/A/1395/2022, interní kód MUNázev: Personalizovaná léčba v dětské onkologii: multimodální theranostický přístup a „N-of-1 clinical trials“
Investor: Masarykova univerzita, Personalizovaná léčba v dětské onkologii: multimodální theranostický přístup a „N-of-1 clinical trials“
VytisknoutZobrazeno: 27. 4. 2024 07:47